Αρχική World News Utility of Genomic Profiling Use for Targeted Therapy in a Phase I... World News Utility of Genomic Profiling Use for Targeted Therapy in a Phase I Setting Reveals that ESCAT I/II Actionable Targets are Associated with Improved Outcomes Από Ogkologos - 6 Μαΐου, 2025 932 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CoPPO study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR What to Expect During a Skin Cancer Screening 31 Μαΐου, 2022 Tyrosine Kinase Inhibitor Prolongs Progression-Free Survival in Rare Neuroendocrine Tumours [ESMO... 20 Σεπτεμβρίου, 2021 New on NCI’s Websites for March 2023 24 Μαρτίου, 2023 Reunión anual de la American Society of Clinical Oncology de 2023:... 6 Ιουνίου, 2023 Φόρτωση περισσοτέρων HOT NEWS For Cancer Screening, COVID-19 Pandemic Creates Obstacles, Opportunities Adding Pembrolizumab to Standard Chemotherapy, Followed by Pembrolizumab Maintenance, Results in... Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance... Study Finds That Gut Bacteria Could Be Used to Minimize Digestive...